56 / 194
Variola virus
Signature (Eroded Specificity):
Assay Cross-reacts with
Cowpox virus
Exclusivity panel
Species
Strain Name
Assay 1
ct for 5 ng DNA
Assay 2
ct for 5 ng DNA
Vaccinia
Copenhagen
Negative
Negative
Vaccinia
WR
Negative
Negative
N ti
Vaccinia
ACAM 2000
ega ve
Negative
Vaccinia
BRZ SERRO
Negative
Negative
Cowpox
CPXV‐NOR1995‐MAN
Negative
Negative
Cowpox
CPXV GER1980‐EP4
19
Negative
Cowpox
CPXV GER1991‐3
18
Negative
Cowpox
CPXV_GER1998_2
17
Negative
Cowpox
CPXV FIN 2000
Negative
Ectromelia
ECTV Moscow
Negative
Negative
Monkeypox
MPXV RCG 2003 358
Negative
Negative
Monkeypox
MPXV USA 2003 044
Negative
Negative
Raccoonpox
RACV V71‐I‐84
Negative
Negative
Skunkpox
SKPV 1991
Negative
Negative
Volepox
VPXV 2004‐CA‐007
Negative
Negative
Camelpox
CMLV‐78‐I‐2379
17
Negative
Taterapox (gerbilpox)
TATV‐71‐I‐016
16
Negative
Parapoxvirus Orf
Vaccine for sheep
Negative
Negative
What We Have Learned About
Variola virus
Diagnostic Assay Development/Validation
Bioinformatic analysis should lead design of validation
panels
Inclusivity panel include all
Variola virus
strains with differences in
assay target region
Exclusivity panel (near neighbor
Orthopoxvirus
) contain viruses
with assay target regions most similar to
Variola virus
Exceedingly difficult to construct uniform panels for all assays
due to high similarity between
Orthopoxviruse
s
Simultaneous identification of multiple
Variola virus
signatures will increase confidence in initial identification/
verification of the pathogen with real-time PCR